首页> 美国卫生研究院文献>Pharmaceutics >Control Strategy for Process Development of High-Shear Wet Granulation and Roller Compaction to Prepare a Combination Drug Using Integrated Quality by Design
【2h】

Control Strategy for Process Development of High-Shear Wet Granulation and Roller Compaction to Prepare a Combination Drug Using Integrated Quality by Design

机译:高剪切湿造粒和辊压缩工艺开发的控制策略通过设计使用综合质量制备组合药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we developed a control strategy for a drug product prepared by high-shear wet granulation and roller compaction using integrated quality by design (QbD). During the first and second stages, we optimized the process parameters through the design of experiments and identified the intermediate quality attributes (IQAs) and critical quality attributes (CQAs) relationship, respectively. In the first stage, we conducted an initial risk assessment by selecting critical process parameters with high impact on IQAs and CQAs and confirmed the correlation between control and response factors. Additionally, we performed Monte Carlo simulations by optimizing the process parameters to deriving and building a robust design space. In the second stage, we identified the IQAs and CQAs relationship for the control strategy, using multivariate analysis (MVA). Based on MVA, in the metformin layer, dissolution at 1 h was significantly correlated with intrinsic dissolution rate and granule size, and dissolution at 3 h was significantly correlated with bulk density and granule size. In dapagliflozin layer, dissolution at 10 min and 15 min was significantly correlated with granule size. Our results suggest that the desired drug quality may result through IQAs monitoring during the process and that the integrated QbD approach utilizing MVA can be used to develop a control strategy for producing high-quality drug products.
机译:在本研究中,我们开发了一种通过设计(QBD)的综合质量通过高剪切湿造粒和辊压缩制备的药品的控制策略。在第一阶段和第二个阶段,我们通过实验设计优化了过程参数,并分别识别了中间质量属性(IQAS)和关键质量属性(CQAS)关系。在第一阶段,我们通过选择对IQAS和CQA的高影响力的关键过程参数进行初始风险评估,并确认了控制和响应因子之间的相关性。此外,我们通过优化进程参数来实现Monte Carlo模拟,从而导出和构建强大的设计空间。在第二阶段,我们通过多变量分析(MVA)确定了对控制策略的IQAS和CQAS关系。基于MVA,在二甲双胍层中,1小时的溶解与内在溶解速率和颗粒尺寸明显相关,并且3小时的溶解与堆积密度和颗粒尺寸明显相关。在Dapagliflozin层中,10分钟的溶解和15分钟与颗粒尺寸显着相关。我们的研究结果表明,期望的药物质量可能会通过IQAS监测在过程中产生,并且利用MVA的综合QBD方法可用于制定生产高质量药品的控制策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号